Investigational drug · Phase 2
NYX-458
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mild Cognitive Impairment, Mild Dementia, Parkinson Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2022 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NYX-458"
First trial start
2019
Nov 14, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NYX-458", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mild Cognitive Impairment
- Mild Dementia
- Parkinson Disease
- Lewy Body Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "NYX-458" as an intervention, largest first.
- NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)Active, not recruiting
AptinyxIndustry
NCT04148391 · 99 participants · Start Nov 14, 2019 · Primary completion Dec 30, 2022
Drug: Placebo Oral Capsule; NYX-458 · For: Mild Cognitive Impairment; Mild Dementia; Parkinson Disease and 1 more
Sites: Scottsdale, Arizona; Fresno, California; Simi Valley, California · 26 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New advances in small molecule drugs targeting NMDA receptors.
Zeng Y, Qu ZY, Zhu QW, et al. · Acta Pharmacol Sin 2026
- Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches.
Degirmenci Y, Angelopoulou E, Georgakopoulou VE, et al. · Medicina (Kaunas) 2023
- Lewy Body Dementia: An Overview of Promising Therapeutics.
Skylar-Scott IA, Sha SJ · Curr Neurol Neurosci Rep 2023
- An overview of the active clinical trials for Parkinson's disease psychosis.
Kwan C, Huot P · Neurodegener Dis Manag 2022
- Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions.
Sun C, Armstrong MJ · Behav Sci (Basel) 2021
- NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.
Barth AL, Schneider JS, Johnston TH, et al. · Mov Disord 2020
Also in development for Mild Cognitive Impairment
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.